Evidence map›Paper›PMID 32814468›Full record

ArticleAmyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis2021

Anticoagulation with warfarin compared to novel oral anticoagulants for atrial fibrillation in adults with transthyretin cardiac amyloidosis: comparison of thromboembolic events and major bleeding.

Lindsey R Mitrani, Jeffeny De Los Santos, Elissa Driggin, Rebecca Kogan, Stephen Helmke, Jeff Goldsmith, Angelo B Biviano, Mathew S Maurer

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed, 2 pooled it
3.0field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 2 syntheses or guidelines pooled it, 61 citations in OpenAlex.

  1. Pooled it
  2. Guideline
  3. Article
  4. Review
  5. Review
  6. Review
  7. [Arrhythmias and amyloidosis].Herzschrittmachertherapie & Elektrophysiologie · 2024
    Review
  8. Review
  9. Review
  10. Article
  11. Review
  12. Review
  13. Review
  14. Review
  15. Article
  16. Review
  17. Article
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Lindsey R MitraniDepartment of Internal Medicine, New York Presbyterian/Columbia University Medical Center, New York City, NY, USA.
Jeffeny De Los SantosDepartment of Cardiology, Columbia University, New York City, NY, USA.
Elissa DrigginDepartment of Internal Medicine, New York Presbyterian/Columbia University Medical Center, New York City, NY, USA.
Rebecca KoganDepartment of Cardiology, Columbia University, New York City, NY, USA.
Stephen HelmkeDepartment of Cardiology, Columbia University, New York City, NY, USA.
Jeff GoldsmithMailman School of Public Health, Columbia University, New York City, NY, USA.
Angelo B BivianoDepartment of Cardiac Electrophysiology, Columbia University, New York City, NY, USA.
Mathew S MaurerDepartment of Cardiology, Columbia University, New York City, NY, USA.ORCID https://orcid.org/0000-0001-5400-5008
Columbia University · USColumbia University Irving Medical Center · US

Funding

Midcareer Mentoring Award for Patient Oriented Research in Geriatric CardiologyK24AG036778 · NIA · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI MAURER, MATHEW S · 2010 to 2020
$1.6M
NIA NIH HHS K24 AG036778
6 · The paper itself

Abstract

backgroundAtrial fibrillation (AF) is common in patients with transthyretin cardiac amyloidosis (ATTR-CA). The optimal strategy to prevent strokes in patients with ATTR-CA and AF is unknown.

objectivesTo compare outcomes in patients with ATTR-CA and AF treated with warfarin versus novel oral anticoagulants (NOACs).

methodsThis study was a retrospective analysis of patients with ATTR-CA stratified by presence or absence of AF and anticoagulation therapy. The primary outcome included a time to event analysis for the combined outcomes of stroke, transient ischaemic attack (TIA), major bleed, or death.

resultsOf 290 patients, 217 patients (74.8%) had AF. Of those with AF (

conclusionPatient with ATTR-CA and AF are at increased risk for stroke compared to patients with ATTR-CA and without AF. Thrombotic events and major bleeds did not differ between those who received warfarin and NOACs.

Indexed as

AgedAged, 80 and overAmyloid Neuropathies, FamilialAtrial FibrillationFactor Xa InhibitorsFemaleHemorrhageHumansIschemic Attack, TransientMaleMiddle AgedStrokeThrombosisWarfarinFactor Xa InhibitorsWarfarinanticoagulationatrial fibrillationcardiac amyloidosisstroketransthyretin

Identifiers

PMID32814468
PMCPMC8018530
OpenAlexW3080859202

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.